{"id":531521,"date":"2021-02-24T07:18:01","date_gmt":"2021-02-24T07:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=531521"},"modified":"2021-02-24T07:18:01","modified_gmt":"2021-02-24T07:18:01","slug":"bk-virus-bkv-infection-pipeline-analysis-shows-tremendous-growth-opportunities-for-the-coming-years-allovir-amplyx-pharmaceutical-sl-vaxigen-hybridize-therapeutics-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/bk-virus-bkv-infection-pipeline-analysis-shows-tremendous-growth-opportunities-for-the-coming-years-allovir-amplyx-pharmaceutical-sl-vaxigen-hybridize-therapeutics-others_531521.html","title":{"rendered":"BK virus (BKV) Infection Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years | AlloVir, Amplyx Pharmaceutical, SL VAXiGEN, Hybridize Therapeutics &#038; Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1614148218.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"BK virus (BKV) Infection Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years | AlloVir, Amplyx Pharmaceutical, SL VAXiGEN, Hybridize Therapeutics &amp; Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1614148218.jpeg\" alt=\"BK virus (BKV) Infection Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years | AlloVir, Amplyx Pharmaceutical, SL VAXiGEN, Hybridize Therapeutics &amp; Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>BK virus (BKV) Infection Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&ldquo;<strong>BK virus (BKV) Infection Pipeline Insight, 2021<\/strong>&rdquo; by DelveInsight highlights the details around the NMIBC pipeline scenario, unmet needs, and Non-Muscle Invasive Bladder Cancer therapeutic assessment of the key pipeline therapies.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bk-virus-bkv-infection-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">BK virus (BKV) Infection<\/a><\/strong>&#8211; The BK virus was first isolated from the urine of a renal transplant recipient with ureteric stenosis in 1971. BK virus is one of 13 known polyomaviruses. Antibodies to BKV are found in approximately 80 to 90 percent of adults worldwide, indicating previous infection or exposure to the virus. Initial infection with BKV is usually asymptomatic or associated with a mild flu-like illness. After primary infection, BKV remains inactive, or latent, in kidney and bladder. A weakened immune system may result in BKV reactivation and cause serious disease. In patients who have had kidney transplant, BKV can lead to the loss of the transplanted kidney.<\/p>\n<p style=\"text-align: justify;\">In the absence of effective treatment, reduction of immunosuppression is recommended; however, lowering of the immunosuppression can lead to acute organ rejection. BKV reactivation in the bladder can cause hemorrhagic cystitis. Severe cases require bladder irrigation, clot evacuation, blood transfusion, stenting and nephrostomy. There are currently no approved treatments for renal nephropathy or hemorrhagic cystitis caused by BKV.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the BK virus (BKV) Infection Companies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>AlloVir<\/li>\n<li>Amplyx Pharmaceuticals<\/li>\n<li>SL VAXiGEN<\/li>\n<li>Hybridize Therapeutics<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">To learn more about BK virus (BKV) Infection Drugs, request&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bk-virus-bkv-infection-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\"> <strong>BK virus (BKV) Infection Drugs Pipeline<\/strong><\/a>&nbsp;Sample Report&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.abnewswire.com\/uploads\/368a77d4f677e15518ac02ac1b50b3fb.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the BK virus (BKV) Infection drugs covered:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>ALVR-105<\/li>\n<li>MAU868<\/li>\n<li>SL-V10<\/li>\n<li>HYB-BKV<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request Sample Page @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bk-virus-bkv-infection-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">BK virus (BKV) Infection Marketed Therapies and Treatment Approaches<\/a>&nbsp;and get a comprehensive understanding of the BK virus (BKV) Infection therapeutic outlook<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>BK virus (BKV) Infection Diagnosis<\/strong><\/p>\n<p style=\"text-align: justify;\">BK virus is detectable in both blood and urine. After BK reactivation, the virus is first detectable in the urine, with viremia developing several weeks later. BK detection by real-time PCR of plasma is very sensitive and specific for the development of BKVN. BKV shedding in the urine is common and can occur in up to 30% of renal transplant recipients. Urine can be screened for BK by cytology or by quantification of urine BK DNA by PCR. Haufen are icosahedral aggregates of polyomavirus particles and Tamm-Horsfall protein that can be detected in the urine of kidney transplant patients with BKVN using negative-staining electron microscopy. Renal biopsy remains the gold standard for the diagnosis of BKVN. It is recommended in patients with a high level of BKV (&gt;4 log copies\/mL), with or without an elevation in serum creatinine.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bk-virus-bkv-infection-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">BK virus (BKV) Infection Treatment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">The mainstay of treatment for BK virus nephropathy is to decrease the immunosuppression, as there is currently no specific antiviral for BK virus. Clearance of BK viremia can be indicative of nephropathy resolution.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">To learn more about BK virus (BKV) Infection Drugs Development, request&nbsp;<strong>BK virus (BKV) Infection Drugs Pipeline<\/strong><strong>&nbsp;Sample Report&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. BK virus (BKV) Infection&nbsp;Overview<\/p>\n<p style=\"text-align: justify;\">3. BK virus (BKV) Infection&nbsp;Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">4. BK virus (BKV) Infection&nbsp;&#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. BK virus (BKV) Infection Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. BK virus (BKV) Infection Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. BK virus (BKV) Infection Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. BK virus (BKV) Infection&nbsp;Product Profiles<\/p>\n<p style=\"text-align: justify;\">13.1. AlloVir: ALVR-105<\/p>\n<p style=\"text-align: justify;\">13.1.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.1.1.1. Product Overview<\/p>\n<p style=\"text-align: justify;\">13.1.1.2. Mechanism of action<\/p>\n<p style=\"text-align: justify;\">13.1.2. Research and Development<\/p>\n<p style=\"text-align: justify;\">13.1.2.1. Clinical Studies<\/p>\n<p style=\"text-align: justify;\">13.1.3. Product Development Activities<\/p>\n<p style=\"text-align: justify;\">13.1.3.1. Collaboration<\/p>\n<p style=\"text-align: justify;\">13.1.3.2. Agreements<\/p>\n<p style=\"text-align: justify;\">13.1.3.3. Acquisition&nbsp;<\/p>\n<p style=\"text-align: justify;\">13.1.3.4. Patent Detail<\/p>\n<p style=\"text-align: justify;\">13.1.4. Tabulated Product Summary<\/p>\n<p style=\"text-align: justify;\">13.1.4.1. General Description Table<\/p>\n<p style=\"text-align: justify;\">Detailed information in the report!<\/p>\n<p style=\"text-align: justify;\"><strong>And Many Others&hellip;<\/strong><\/p>\n<p style=\"text-align: justify;\">14. BK virus (BKV) Infection&nbsp;Key Companies<\/p>\n<p style=\"text-align: justify;\">15. BK virus (BKV) Infection&nbsp;Key Products<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. BK virus (BKV) Infection&nbsp;Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. BK virus (BKV) Infection&nbsp;Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. BK virus (BKV) Infection&nbsp;Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;<strong>PharmDelve<\/strong>.<\/p>\n<p style=\"text-align: justify;\">DelveInsght&rsquo;s&nbsp;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/consulting\/competitive-intelligence-services\">Competitive Intelligence Service<\/a><\/strong>&nbsp;includes a multidimensional coverage, helping to keep track of competitors and gain traction in the dynamic market by overcoming the challenges and expediting business growth through a strategic and tactical approach.&nbsp; &nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=bk-virus-bkv-infection-pipeline-analysis-shows-tremendous-growth-opportunities-for-the-coming-years-allovir-amplyx-pharmaceutical-sl-vaxigen-hybridize-therapeutics-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/bk-virus-bkv-infection-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/bk-virus-bkv-infection-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/bk-virus-bkv-infection-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=bk-virus-bkv-infection-pipeline-analysis-shows-tremendous-growth-opportunities-for-the-coming-years-allovir-amplyx-pharmaceutical-sl-vaxigen-hybridize-therapeutics-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BK virus (BKV) Infection Pipeline &nbsp; &ldquo;BK virus (BKV) Infection Pipeline Insight, 2021&rdquo; by DelveInsight highlights the details around the NMIBC pipeline scenario, unmet needs, and Non-Muscle Invasive Bladder Cancer therapeutic assessment of the key pipeline therapies.&nbsp; &nbsp; BK virus &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/bk-virus-bkv-infection-pipeline-analysis-shows-tremendous-growth-opportunities-for-the-coming-years-allovir-amplyx-pharmaceutical-sl-vaxigen-hybridize-therapeutics-others_531521.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-531521","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=531521"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531521\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=531521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=531521"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=531521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}